Tasigna patent expiration?

When does the patent for Tasigna expire?

The patent for Tasigna, a medication used to treat certain types of leukemia and other blood disorders, is held by Novartis. According to DrugPatentWatch.com, the original patent for Tasigna (nilotinib) expired in the United States on March 1, 2020 [1]. However, Novartis has received several patent extensions and maintains exclusivity rights through various mechanisms.

What is the current patent status?

The US Food and Drug Administration (FDA) has granted several exclusivity periods for Tasigna, including a five-year orphan drug exclusivity that expired in 2017 [2]. Additionally, Novartis has filed supplementary patents that further extend the expiration date. According to DrugPatentWatch.com, the latest patent expiration date for a Tasigna patent in the United States is April 6, 2024 [3].

What implications does the patent expiration have?

The patent expiration of Tasigna may lead to increased competition from generic and biosimilar manufacturers. However, the complexity of the medication's formulation and manufacturing process may limit the entry of new competitors. The generic market for Tasigna is still developing, and it remains unclear how much of the market will be captured by generic products.

Who makes generic or biosimilar versions of Tasigna?

Several companies have received FDA approval to manufacture generic or biosimilar versions of Tasigna, including Teva Pharmaceutical Industries and Accord Healthcare [4]. However, their products may not be available in the market immediately due to competition from the branded product and patent-related challenges.

What are the potential side effects and patient concerns?

As with any medication, Tasigna can cause side effects such as skin rash, nausea, and diarrhea [5]. Patients on Tasigna should discuss potential risks and concerns with their healthcare provider before switching to a generic or biosimilar product.

References:

[1] DrugPatentWatch.com (2020). Nilotinib (Tasigna) Patent Expiration.

[2] US FDA (2017). Nilotinib (Tasigna) - Orphan Drug Exclusivity.

[3] DrugPatentWatch.com (2023). Nilotinib (Tasigna) Patent Expiration.

[4] US FDA (2020). Nilotinib (Tasigna) - Generic Approval.

[5] Novartis. (2020). Tasigna (nilotinib) label.